NCT04508816View on ClinicalTrials.gov

Anti-EGFR Therapy Plus IMRT Concurrent Chemoradiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

January 1, 2016

Primary Completion Date

October 1, 2020

Study Completion Date

October 1, 2020

Conditions
Nasopharyngeal Carcinoma
Interventions
DRUG

cetuximab (CTX) or nimotuzumab (NTZ)

The patients will receive IMRT combined with anti-EGFR monoclonal antibody concurrent chemoradiotherapy. The specific treatment description is included in arm description.

Trial Locations (1)

200032

Xiaoshen Wang, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER

NCT04508816 - Anti-EGFR Therapy Plus IMRT Concurrent Chemoradiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy | Biotech Hunter | Biotech Hunter